Press releases

Versantis Awarded Innosuisse Grant of CHF475,000 to Develop Point of Care Device to Monitor Blood Ammonia in Liver Disease Patients

Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO

Versantis to Present Positive Phase 1b Data at AASLD for VS-01 in Patients with Decompensated Cirrhosis

Versantis Appoints Leading Hepatologist Prof Dr Katharina Staufer as Chief Medical Officer

Versantis Receives U.S. FDA Orphan Drug Designation for VS-01

Versantis Announces Positive Phase 1b Results for VS-01 in Patients with Decompensated Cirrhosis

Versantis Appoints Seasoned Pharma Executive Christopher Seaton to Board

Versantis Receives FDA Rare Pediatric Disease Designation for VS-01 for the Treatment of Urea Cycle Disorders

Versantis closes CHF 16M Series B financing round to advance clinical development of novel therapeutics for liver disease

Successful initiation for FiH Study with VS-01

Versantis Strengthens Leadership Team with Appointment of Dr. Med.Sophie Biguenet as Chief Medical Officer

Versantis Establishes Medical Advisory Board comprising five notorious international authorities in hepatology, intensive care, and nephrology. They joined versantis to transform the care of acute liver diseases.

Versantis Announces FDA Grants Orphan Drug Designation to VS-01 for the Treatment of Acute-on-Chronic Liver Failure

VERSANTIS RAISES CHF 4.4 MILLION IN SERIES A FINANCING TO ADVANCE NEW GENERATION OF LIVER DISEASE MEDICINES

The EMA issued a positive opinion on the orphan drug designation for VS-01 for the treatment of acute liver failure.